
WEDNESDAY, Sept. 28, 2022 (HealthDay) — Japanese drugmaker Eisai on Wednesday said its experimental drug lecanemab helped slow thinking declines among people in the early stages of Alzheimer’s disease. The findings from a phase 3 clinical trial have yet to be peer-reviewed in any medical journal. But according to a company news release, “lecanemab treatment… read on > read on >